BACKGROUND: In July 2016, Sri Lanka replaced 1 intramuscular dose of inactivated poliovirus vaccine (IPV) with 2 doses of intradermal fractional-dose IPV (fIPV) in its routine immunization schedule. We carried out a survey of seroprevalence of antipolio antibodies in children who received 2 fIPV doses and compared it with those who received 1 full IPV dose. METHODS: Children born between March and December 2016 were randomly selected from 3 Sri Lankan districts (Colombo, Badulla, and Anuradhapura). Serum samples were collected and tested for presence of neutralizing antibodies to poliovirus types 1, 2, and 3. RESULTS: Seroprevalence of antipolio antibodies was 100% in all districts for poliovirus type 1 and poliovirus type 3; it ranged between 90% and 93% for poliovirus type 2 (PV2) in children who received 1 full IPV dose and between 78% and 100% in those receiving 2 fIPV doses (P = .22). The median reciprocal titers of anti-PV2 antibodies were similar in children who received full-dose IPV and those who received fIPV (1:64 vs 1:45, respectively; P = .11). CONCLUSIONS: Our study demonstrated not only that Sri Lanka succeeded in maintaining very high primary immunization coverage also but that it is feasible for a national immunization program to implement fIPV immunization and achieve high coverage with intradermal application. The seroprevalence of anti-PV2 antibodies did not decrease after the introduction of fIPV.
BACKGROUND: In July 2016, Sri Lanka replaced 1 intramuscular dose of inactivated poliovirus vaccine (IPV) with 2 doses of intradermal fractional-dose IPV (fIPV) in its routine immunization schedule. We carried out a survey of seroprevalence of antipolio antibodies in children who received 2 fIPV doses and compared it with those who received 1 full IPV dose. METHODS: Children born between March and December 2016 were randomly selected from 3 Sri Lankan districts (Colombo, Badulla, and Anuradhapura). Serum samples were collected and tested for presence of neutralizing antibodies to poliovirus types 1, 2, and 3. RESULTS: Seroprevalence of antipolio antibodies was 100% in all districts for poliovirus type 1 and poliovirus type 3; it ranged between 90% and 93% for poliovirus type 2 (PV2) in children who received 1 full IPV dose and between 78% and 100% in those receiving 2 fIPV doses (P = .22). The median reciprocal titers of anti-PV2 antibodies were similar in children who received full-dose IPV and those who received fIPV (1:64 vs 1:45, respectively; P = .11). CONCLUSIONS: Our study demonstrated not only that Sri Lanka succeeded in maintaining very high primary immunization coverage also but that it is feasible for a national immunization program to implement fIPV immunization and achieve high coverage with intradermal application. The seroprevalence of anti-PV2 antibodies did not decrease after the introduction of fIPV.
Authors: P Más Lago; V M Cáceres; M A Galindo; H E Gary; M Valcarcel; J Barrios; L Sarmiento; I Avalos; J A Bravo; R Palomera; M Bello; R W Sutter; M A Pallansch; C A de Quadros Journal: Int J Epidemiol Date: 2001-10 Impact factor: 7.196
Authors: Pedro Más Lago; Howard E Gary; Luis Sarmientos Pérez; Victor Cáceres; Julio Barrios Olivera; Rosa Palomera Puentes; Marité Bello Corredor; Patricia Jímenez; Mark A Pallansch; Roberto González Cruz Journal: Int J Epidemiol Date: 2003-10 Impact factor: 7.196
Authors: Sonia Resik; Alina Tejeda; Roland W Sutter; Manuel Diaz; Luis Sarmiento; Nilda Alemañi; Gloria Garcia; Magilé Fonseca; Lai Heng Hung; Anna-Lea Kahn; Anthony Burton; J Mauricio Landaverde; R Bruce Aylward Journal: N Engl J Med Date: 2013-01-31 Impact factor: 91.245
Authors: Edwin J Asturias; Ananda S Bandyopadhyay; Steve Self; Luis Rivera; Xavier Saez-Llorens; Eduardo Lopez; Mario Melgar; James T Gaensbauer; William C Weldon; M Steven Oberste; Bhavesh R Borate; Chris Gast; Ralf Clemens; Walter Orenstein; Miguel O'Ryan G; José Jimeno; Sue Ann Costa Clemens; Joel Ward; Ricardo Rüttimann Journal: Lancet Date: 2016-05-19 Impact factor: 79.321
Authors: Ali F Saleem; Ondrej Mach; Mohammad T Yousafzai; Asia Khan; William C Weldon; M Steven Oberste; Syed S Zaidi; Muhammad M Alam; Farheen Quadri; Roland W Sutter; Anita K M Zaidi Journal: J Infect Dis Date: 2018-01-17 Impact factor: 5.226
Authors: Deepa Gamage; Paba Palihawadana; Ondrej Mach; William C Weldon; Steven M Oberste; Roland W Sutter Journal: J Epidemiol Glob Health Date: 2015-07-09
Authors: Umar Farooq Bullo; Jaishri Mehraj; Syed Musa Raza; Shumaila Rasool; Noreen Naz Ansari; Ahmed Ali Shaikh; Zamir Ali Phul; Sohail Ahmed Memon; Rehan Iqbal Baloch; Zahoor Ahmed Baloch; Shoukat Ali Chandio Journal: BMC Public Health Date: 2021-01-06 Impact factor: 3.295
Authors: Ali Faisal Saleem; Ondrej Mach; Mohammad Tahir Yousafzai; Zaubina Kazi; Attaullah Baig; Muhammad Sajid; Vishali Jeyaseelan; Roland W Sutter; Anita K M Zaidi Journal: J Infect Dis Date: 2021-04-08 Impact factor: 5.226